Abstract: The present invention provides a preventive or therapeutic agent for hyperlipidemia, comprising as an active ingredient a heterocyclic compound of the formula [1], or a pharmaceutically acceptable salt thereof: R1-Het-D-E??[1] wherein: R1 is optionally substituted aryl or aromatic heterocyclic group, Het is a divalent aromatic heterocyclic group, D is alkylene, alkenylene, alkynylene, or the like, and E is carboxy, or the like, and novel compounds among the heterocyclic compounds of the formula [1] above, which has blood triglyceride lowering effect, LDL-C lowering effect, and blood glucose lowering effect and blood insulin lowering effect, or HDL-C increasing effect or atherogenic index lowering effect all together, and hence is useful in the prevention or treatment of hyperlipidemia, arteriosclerosis, diabetes mellitus, hypertension, obesity, and the like.

Abstract: The present invention provides a preventive or therapeutic agent for hyperlipidemia, comprising as an active ingredient a heterocyclic compound of the formula [1], or a pharmaceutically acceptable salt thereof: wherein: R1 is optionally substituted aryl or aromatic heterocyclic group, Het is a divalent aromatic heterocyclic group, D is alkylene, alkenylene, alkynylene, or the like, and E is carboxy, or the like, and novel compounds among the heterocyclic compounds of the formula [1] above, which has blood triglyceride lowering effect, LDL-C lowering effect, and blood glucose lowering effect and blood insulin lowering effect, or HDL-C increasing effect or atherogenic index lowering effect all together, and hence is useful in the prevention or treatment of hyperlipidemia, arteriosclerosis, diabetes mellitus, hypertension, obesity, and the like.

Abstract: The present invention provides a preventive or therapeutic agent for hyperlipidemia, comprising as an active ingredient a heterocyclic compound of the formula [1], or a pharmaceutically acceptable salt thereof: R1-Het-D-E [1] wherein: R1 is optionally substituted aryl or aromatic heterocyclic group, Het is a divalent aromatic heterocyclic group, D is alkylene, alkenylene, alkynylene, or the like, and E is carboxy, or the like, and novel compounds among the heterocyclic compounds of the formula [1] above, which has blood triglyceride lowering effect, LDL-C lowering effect, and blood glucose lowering effect and blood insulin lowering effect, or HDL-C increasing effect or atherogenic index lowering effect all together, and hence is useful in the prevention or treatment of hyperlipidemia, arteriosclerosis, diabetes mellitus, hypertension, obesity, and the like.

Abstract: The present invention provides a preventive or therapeutic agent for hyperlipidemia, comprising as an active ingredient a heterocyclic compound of the formula [1], or a pharmaceutically acceptable salt thereof: R1-Het-D-E [1] wherein: R1 is optionally substituted aryl or aromatic heterocyclic group, Het is a divalent aromatic heterocyclic group, D is alkylene, alkenylene, alkynylene, or the like, and E is carboxy, or the like, and novel compounds among the heterocyclic compounds of the formula [1] above, which has blood triglyceride lowering effect, LDL-C lowering effect, and blood glucose lowering effect and blood insulin lowering effect, or HDL-C increasing effect or atherogenic index lowering effect all together, and hence is useful in the prevention or treatment of hyperlipidemia, arteriosclerosis, diabetes mellitus, hypertension, obesity, and the like.

Abstract: The present invention provides a preventive or therapeutic agent for hyperlipidemia, comprising as an active ingredient a heterocyclic compound of the formula [1], or a pharmaceutically acceptable salt thereof: R1—Het-D-E??[1] wherein: R1 is optionally substituted aryl or aromatic heterocyclic group, Het is a divalent aromatic heterocyclic group, D is alkylene, alkenylene, alkynylene, or the like, and E is carboxy, or the like, and novel compounds among the heterocyclic compounds of the formula [1] above, which has blood triglyceride lowering effect, LDL-C lowering effect, and blood glucose lowering effect and blood insulin lowering effect, or HDL-C increasing effect or atherogenic index lowering effect all together, and hence is useful in the prevention or treatment of hyperlipidemia, arteriosclerosis, diabetes mellitus, hypertension, obesity, and the like.

Abstract: The present invention provides a preventive or therapeutic agent for hyperlipidemia, comprising as an active ingredient a heterocyclic compound of the formula [1], or a pharmaceutically acceptable salt thereof: wherein: R1 is optionally substituted aryl or aromatic heterocyclic group, Het is a divalent aromatic heterocyclic group, D is alkylene, alkenylene, alkynylene, or the like, and E is carboxy, or the like, and novel compounds among the heterocyclic compounds of the formula [1] above, which has blood triglyceride lowering effect, LDL-C lowering effect, and blood glucose lowering effect and blood insulin lowering effect, or HDL-C increasing effect or atherogenic index lowering effect all together, and hence is useful in the prevention or treatment of hyperlipidemia, arteriosclerosis, diabetes mellitus, hypertension, obesity, and the like.

Abstract: There is disclosed a method of converting a software program for a single processor to that for a multiprocessor. In the method, to prepare an execute form program for operating software running on a single memory space on the multiprocessor, a source file is allocated to each processor by an object file unit to prepare the execute form program for each processor. The execute form program is mounted on the memory space managed by each processor with an arrangement in which addresses are prevented from being duplicated among the processors.

Abstract: The present invention provides a preventive or therapeutic agent for hyperlipidemia, comprising as an active ingredient a heterocyclic compound of the formula [1], or a pharmaceutically acceptable salt thereof:

Abstract: A method of planning, a computer program, and a computer product for realizing supply-demand planning in a supply chain make a computer execute fetching switching information corresponding to a base and an item from a table, which contains the switching information corresponding to the base and the item, and performing, depending upon the switching information, either of supply-demand planning per order and supply-demand planning based on total amount of orders.

Abstract: An e-mail communication system, in which bothering e-mails can be prevented to transmit to recipients, is provided. In case that a sender (subscriber) connected to an Internet service provider transmitted an e-mail to recipients (subscribers) connected to the Internet service provider, when the e-mail was an unwelcome e-mail (bothering e-mail) to the recipients, each of the recipients transmit a refusal notice to a data server for addresses transmitted refusal e-mails by using e-mails via an e-mail server provided by the Internet service provider. The data server for addresses transmitted refusal e-mails stores the transmitted refusal notices. When the number of the refusal notices per a unit period exceeded a threshold value, the Internet service provider makes the sender stop transmitting e-mails from now on.

Abstract: The present invention provides a preventive or therapeutic agent for hyperlipidemia, comprising as an active ingredient a heterocyclic compound of the formula [1], or a pharmaceutically acceptable salt thereof:

Abstract: A voice component effectiveness judging section takes as input voice parameters from a voice component extraction section and determines whether or not an effective voice component is present that is sufficient for transmission to base stations. The output from the voice component effectiveness judging section is sent to a control section. If this output indicates that an effective voice component is present, the controller controls a modulator, transmitter, and synthesizer such that voice transmission is carried out in the transmission time slot. If the output indicates that an effective voice component is not present, the controller effects control such that in the transmission time slot, the synthesizer tunes to the radio frequency of the control channel of the adjacent base stations and the receiver and demodulator measure received fields.

Abstract: In a time-division multiple access cellular mobile communication system, first and second base stations respectively provide coverages over adjacent cells. A receiver station is located in a region where the coverages of the base stations partially overlap for receiving first and second synchronization signals from the first and second base stations, respectively, to detect a time difference between the received synchronization signals. The receiver station then communicates time difference data to the first and second base stations, the data representing the detected time difference and channel identifiers of the first and second base stations. The first and second base stations time-division multiplex the time difference data with a downlink traffic signal and broadcast the multiplexed time difference data.